Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04008927
Other study ID # ANRS 95050 ICONE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 18, 2020
Est. completion date September 10, 2021

Study information

Verified date July 2022
Source ANRS, Emerging Infectious Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to assess the effectiveness of a community-based model of HCV mass screening associated with an immediate HCV treatment on the cascade of care among active drug users (DUs) in the city of Montpellier, France.


Description:

Active DUs will be recruited using a Respondent-Driven Sampling (RDS) method. Hosted in the temporary community care facility (the research site), located outside the existing care facilities in the city, participants will benefit from HCV/HIV/HBV screening, on-site measurement of HCV-RNA and liver fibrosis, early treatment, treatment follow-up and risk and harm reduction tools related to their risk practices. Peers will be present in this unique structure and will accompany participants throughout their treatment. Participants will be referred during treatment to existing care facilities but followed up in the research up to 44 to 48 weeks after initiation of treatment to assess the rate of re-infection. The number of active DUs in the population will be estimated by using a capture/recapture method nested in the RDS survey Secondary objectives of the research are: - To estimate the seroprevalence of hepatitis C in active DUs in Montpellier; - To estimate the size of the active DUs population in the city of Montpellier using a capture/recapture method; - To estimate HCV care cascade steps in active DUs in Montpellier; - To identify the factors associated with HCV treatment failure; - To determine the proportion of treated and cured HCV patients who re-infect within months after end of treatment; - To estimate the seroprevalence of hepatitis B and HIV infection in active DUs in Montpellier.


Recruitment information / eligibility

Status Completed
Enrollment 554
Est. completion date September 10, 2021
Est. primary completion date September 10, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age> 18 years - Be an active drug user defined by: 1. Report current and regular (Last uptake no more than 3 days ago and at least 10 times a month) use of illicit psychoactive substances other than cannabis (heroin, amphetamines, cocaine, MDMA/ecstasy, cathinones) or misused medications (methadone, buprenorphine, opiate drugs, methylphenidate, ketamine) AND 2. Positive urine test for a psychoactive substance other than cannabis (Heroin, amphetamines, cocaine, MDMA/ecstasy, cathinones) or a misused medication (methadone, buprenorphine, opiate drugs, methylphenidate, ketamine). Exclusion Criteria: - Inability to understand the study - Be under guardianship, curatorship or future protection mandate - Lack of informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
HCV screening
All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
Diagnosis of hepatitis C
HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL). In addition a measure of the liver stiffness will be performed.
Drug:
HCV treatment
Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.

Locations

Country Name City State
France CHU Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases

Country where clinical trial is conducted

France, 

References & Publications (7)

Blackburn NA, Patel RC, Zibbell JE. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014. Public Health Rep. 2016 May-Jun;131 Suppl 2:91-7. — View Citation

Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hézode C, Pawlotsky JM. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect. 2016 May;22(5):459.e1-6. doi: 10.1016/j.cmi.2016.01.009. Epub 2016 Jan 22. — View Citation

Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. — View Citation

Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13. — View Citation

Des Jarlais D, Khue PM, Feelemyer J, Arasteh K, Thi Huong D, Thi Hai Oanh K, Thi Giang H, Thi Tuyet Thanh N, Vinh VH, Heckathorn DD, Moles JP, Vallo R, Quillet C, Rapoud D, Michel L, Laureillard D, Hammett T, Nagot N. Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam. Drug Alcohol Depend. 2018 Apr 1;185:106-111. doi: 10.1016/j.drugalcdep.2017.11.033. Epub 2018 Feb 2. — View Citation

Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9. — View Citation

Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, Chevaliez S, Pillonel J, Jauffret-Roustide M, LE Strat Y. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017 Apr;145(5):895-907. doi: 10.1017/S0950268816002934. Epub 2016 Dec 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of treated and cured DU participants. Proportion of treated and cured DU participants among those with a detectable HCV-RNA at pre-inclusion. SVR12 (12 weeks after end of HCV treatment)
Secondary Proportion of participants with a HCV positive serology Proportion of participants with a HCV positive serology among all participants Screening RDS
Secondary Estimated number of drug users in the city of Montpellier Estimated number of drug users in the city of Montpellier by capture/recapture survey Screening RDS
Secondary Proportion of participants with detectable HCV-RNA Proportion of patients with HCV RNA > 10 IU/mL among those with positive HCV serology Screening RDS
Secondary Proportion of participants initiating anti-viral treatment Proportion of patients with chronic hepatitis who initiate the treatment among patients with HCV-RNA >10 UI/mL Day 0
Secondary Rate of reinfection Proportion of cured participants re-infected within months after end of treatment defined by positive HCV-RNA of different genotype at SVR12 or by positive HCV-RNA at W44/48 Week 48
Secondary Hepatitis B infection rate Proportion of participants with HBs antigene and positive B-DNA at baseline Screening RDS
Secondary HIV infection rate and ART coverage Proportion of participants with positive HIV serology at baseline and proportion of participants with anti-viral treatment among HIV positive participants at baseline Screening RDS
See also
  Status Clinical Trial Phase
Completed NCT05468879 - Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects N/A
Not yet recruiting NCT06395129 - Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Completed NCT02293057 - Gender-Responsive Drug Use Treatment for Juvenile Justice Girls N/A
Completed NCT01941108 - Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care N/A
Completed NCT01380613 - Neighborhoods, Networks, Depression, and HIV Risk Phase 2
Withdrawn NCT00914719 - Alcohol Use and Sexual Risk: An Intervention N/A
Recruiting NCT03671629 - Pharmacist Intervention to Reduce Drug-related Readmissions Among the Elderly N/A
Completed NCT03290391 - Linking Infectious and Narcology Care-Part II Phase 4
Completed NCT03627546 - HCV Seek, Test and Rapid Treatment for Young PWID N/A
Not yet recruiting NCT03967262 - Secondary Prevention and Recidivism Reduction in Trauma Patients N/A
Completed NCT03079856 - Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER N/A
Completed NCT03855410 - Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention N/A
Terminated NCT02457949 - The Impact of Alternative Social Assistance Disbursement on Drug-related Harm N/A
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Recruiting NCT04717856 - Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA N/A
Completed NCT00249496 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1 N/A
Recruiting NCT05597865 - Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents N/A
Completed NCT05553054 - Drug Wastage : Observational Study in Intensive Care Units in France
Completed NCT03718520 - The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity